Autophagy Infiltrates Every Cancer Hallmark. Here’s Why That Changes Treatment Strategy.

Cancer cells are remarkably good at staying alive under conditions that would kill normal cells, and a mounting body of evidence points to autophagy as one of their most versatile survival tools. A comprehensive review published in Theranostics in June 2026 by Liu and colleagues argues that autophagy, the cellular process by which damaged or surplus components are packaged and digested in lysosomes, does not merely intersect with cancer biology at one or two points. It is woven into all 14 recognized cancer hallmarks, from uncontrolled proliferation to immune evasion, functioning sometimes as a tumor suppressor and sometimes as an accelerant depending on context.

Autophagy's Double-Edged Role Across All 14 Cancer Hallmarks

The hallmarks of cancer framework, first proposed in 2000 and updated most recently in 2022 and 2026, catalogs the core capabilities a cell must acquire to become malignant. The 2026 revision organizes these into a four-dimensional framework covering nine core hallmarks, five enabling characteristics, the cellular constituents of the tumor microenvironment, and systemic interactions. The review's central claim is that autophagy operates as an active participant in each category, not a passive bystander.

On the proliferative side, autophagy directly fuels tumor growth by degrading negative regulators. The tumor suppressor PTEN, which normally restrains growth signaling, is broken down through autophagic pathways. So is p53, the genome guardian. At the same time, a selective form of autophagy called mitophagy clears damaged mitochondria, reducing reactive oxygen species (ROS) that would otherwise trigger cell death. The net result is a cell that grows faster, resists apoptosis, and erodes telomeres more slowly, supporting what the hallmarks framework calls limitless replicative potential. Prior work on autophagy's paradoxical roles in cancer has flagged exactly this duality: the same process can tip a cell toward survival or death depending on the stimulus, and the mechanistic reasons for that switch are still being worked out.

How Autophagy Drives Tumor Spread and Metabolic Rewiring

Beyond proliferation, autophagy plays a hands-on role in the dissemination hallmarks. Invasion and metastasis require cancer cells to break away from their original location, enter the bloodstream, and colonize distant organs. Autophagy assists at multiple steps. The scaffold protein p62/SQSTM1 mediates autophagic degradation of E-cadherin, the molecular glue that holds epithelial cells together; losing E-cadherin allows cells to adopt a more migratory, mesenchymal identity through a process called epithelial-to-mesenchymal transition (EMT). Autophagy also promotes the secretion of proangiogenic exosomes, small vesicles that stimulate the growth of new blood vessels to feed the expanding tumor, a process documented in non-small cell lung cancer involving the protein CEP55.

Metabolic reprogramming, the shift toward aerobic glycolysis known as the Warburg effect, depends on autophagy to recycle nutrients under the nutrient-poor conditions common inside solid tumors. Hypoxia, a near-universal feature of growing tumors, stabilizes the transcription factor HIF-1α, which in turn upregulates mitophagy receptors including BNIP3, NIX, and FUNDC1. The result is a self-reinforcing loop in which low oxygen drives autophagy, autophagy sustains metabolism, and sustained metabolism enables further tumor growth.

Immune Evasion and Inflammation: Autophagy as Regulator

The review pays particular attention to autophagy's role in the microenvironmental and immune hallmarks, an area of growing clinical relevance given the rise of immunotherapy. Tumors evade immune destruction partly by downregulating MHC-I molecules that present tumor antigens to T cells, and partly by upregulating the checkpoint protein PD-L1, which sends a "don't kill me" signal. Autophagy modulates both mechanisms. Meanwhile, autophagy suppresses the NLRP3 inflammasome, a molecular sensor that would otherwise trigger inflammatory cytokine release, and regulates the secretory phenotype of senescent cells by degrading the transcription factor GATA4.

The coupling of inflammation to immune evasion runs through the p62/NF-κB signaling axis, and research into autophagy and chemoresistance has shown that cancer cells exploit these same cytoprotective mechanisms as a survival strategy when exposed to chemotherapy. Tumors with high autophagic flux, essentially running the self-digestion program at high speed, appear to be particularly adept at weathering drug treatment, a finding with direct implications for how clinicians sequence therapies.

Therapeutic Strategies and the Challenge of Context-Dependency

The review catalogs four broad classes of autophagy-targeting drugs. Core modulators such as Spautin-1 and SAR405 block autophagy initiation. Lysosome-targeting agents including chloroquine and hydroxychloroquine disrupt the acidic environment that lysosomes need to digest their cargo. Upstream pathway modulators like rapamycin and metformin work through mTOR and AMPK, broad-acting nutrient-sensing hubs. A fourth category, indirect modulators such as salinomycin, perturbs other cellular systems with secondary effects on autophagy.

Clinical trials with chloroquine and hydroxychloroquine have produced mixed results, and the review is candid about why: autophagy inhibition that helps in one tumor type or treatment context can be neutral or even counterproductive in another. The authors argue that a tumor's "hallmark dependency landscape" and its baseline rate of autophagic flux should, in principle, predict whether inhibiting or amplifying autophagy will do more harm to the cancer than to the patient. The practical obstacle is that no validated, real-time method for measuring autophagic flux in living tumor tissue currently exists. Standard techniques such as transmission electron microscopy and Western blotting capture static snapshots rather than the dynamic process clinicians would actually need to track.

Open Questions That Will Define the Next Phase of Research

The historical challenge of resolving autophagy's context-dependent roles remains the central obstacle, and the 2026 review does not claim to have solved it. Several specific gaps stand out. Most available small-molecule autophagy inhibitors are not selective for autophagy alone, meaning they hit other targets and generate toxicity in normal tissues that depend on autophagy for housekeeping functions. Systemic inhibition of autophagy risks damaging the liver, nervous system, and immune cells that rely on the pathway continuously. The authors also note that some indirect modulators with interesting preclinical profiles, cytochalasin E among them, have limited translational feasibility.

The path forward, according to the review, runs through better biomarkers for patient stratification, more selective autophagy inhibitors, and combination regimens designed around the specific hallmarks a given tumor relies on. That is a considerable agenda, and most of it remains investigational. What the review does establish clearly is that autophagy is not a single switch to be flipped. It is a dynamic, context-sensitive program that cancer biology has co-opted at nearly every stage of tumor development, from the first growth signal to the final immune escape. Understanding its full circuitry may be one of the more consequential challenges in translational oncology over the next decade.

Evidence rating

INVESTIGATIONAL — 63/100

Caveats:

• This is a narrative review, not a clinical trial or experimental study — it synthesizes existing literature rather than generating new data.
• No funding source is disclosed.
• Autophagy's role in cancer is highly context-dependent; conclusions may not generalize across tumor types or treatment settings.
• Clinical trials with autophagy inhibitors have shown inconsistent results, and reliable biomarkers to guide patient selection do not yet exist.

Narrative review synthesizing published literature on autophagy's mechanistic role across 14 cancer hallmarks; no original experimental data are presented. Conclusions are supported by accumulated prior work but are subject to the well-documented context-dependency of autophagy in oncology. Clinical translation remains limited by the absence of validated flux biomarkers and inconsistent trial outcomes.